中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2013年
1期
69-71
,共3页
李明亮%钟跃思%徐见亮%姚志成%颜见%邓美海
李明亮%鐘躍思%徐見亮%姚誌成%顏見%鄧美海
리명량%종약사%서견량%요지성%안견%산미해
脐带间质干细胞%骨髓间质干细胞%肝纤维化%细胞移植
臍帶間質榦細胞%骨髓間質榦細胞%肝纖維化%細胞移植
제대간질간세포%골수간질간세포%간섬유화%세포이식
Umbilical cord mesenchymal stem ceils%Bone marrow mesenchymal stem cells%Hepatic fibrosis%Cell transplantation
目的 观察脐带间质干细胞(UMSCs)和骨髓间质干细胞(BMSCs)对CCl4诱导大鼠肝纤维化的治疗作用.方法 通过50％ CCl4橄榄油皮下注射10周建立大鼠肝纤维化模型,随机平均分为UMSCs组、BMSCs组及空白对照组,UMSCs组经尾静脉输注1ml UMSCs(2×109/L),BMSCs组输注1 ml BMSCs (2×109/L),空白对照组输注1 ml生理盐水,移植处理3周后处死所有大鼠.抽取血液检测移植处理前后各组大鼠肝功能指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBIL)、白蛋白(ALB)],取肝脏标本苏木素-伊红(HE)染色行病理检查及量化计分.结果 (1)移植处理3周后,与空白对照组大鼠ALT、AST、TBIL指标[(637.60±42.38) U/L、(525.80 ±40.20) U/L、(17.26±0.68)μmol/L]比较,BMSCs组[(168.80±8.35) U/L、(352.00±33.64) U/L、(14.12±0.34),mol/L]和UMSCs组[(163.60±7.30) U/L、(339.00±44.94) U/L、(13.96±0.29) μmol/L]均降低,差异均有统计学意义(P＜0.05),ALB指标差异无统计学意义(P＞0.05)；与BMSCs组比较,UMSCs组大鼠ALT、AST、TBIL及ALB指标差异均无统计学意义(p＞0.05).(2)与移植处理前各组ALT、AST、TBIL指标[空白对照组:(337.80±13.97)U/L、(436.40±23.27) U/L、(15.20±0.57) μmol/L; BMSCs组:(337.40±14.10) U/L、(439.40±15.27) U/L、(15.52±0.47) μmol/L;UMSCs组:(337.40±16.21) U/L、(437.20±25.15) U/L、(15.54±0.72).μmol/L]比较,处理3周后BMSCs组和UMSCs组相应指标均降低,空白对照组相应指标均升高,差异均有统计学意义(P＜0.05)；移植处理前后各组大鼠ALB指标差异无统计学意义(P＞0.05).(3)与空白对照组比较,BMSCs组和UMSCs组肝脏炎症活动度及纤维化程度均减轻,量化计分(空白对照组:13.20±1.79、15.90±5.28;BMSCs组:4.70±1.57、6.00±1.70; UMSCs组:4.30±1.79、5.90±0.82)差异有统计学意义(P＜ 0.05)；UMSCs组与BMSCs组计分差异无统计学意义(P＞0.05).结论 UMSCs和BMSCs移植均可改善CCl4诱导的肝纤维化大鼠的肝功能,减轻肝脏的炎症活动度及纤维化程度,其中UMSCs的改善效果稍优于BMSCs.
目的 觀察臍帶間質榦細胞(UMSCs)和骨髓間質榦細胞(BMSCs)對CCl4誘導大鼠肝纖維化的治療作用.方法 通過50％ CCl4橄欖油皮下註射10週建立大鼠肝纖維化模型,隨機平均分為UMSCs組、BMSCs組及空白對照組,UMSCs組經尾靜脈輸註1ml UMSCs(2×109/L),BMSCs組輸註1 ml BMSCs (2×109/L),空白對照組輸註1 ml生理鹽水,移植處理3週後處死所有大鼠.抽取血液檢測移植處理前後各組大鼠肝功能指標[穀丙轉氨酶(ALT)、穀草轉氨酶(AST)、總膽紅素(TBIL)、白蛋白(ALB)],取肝髒標本囌木素-伊紅(HE)染色行病理檢查及量化計分.結果 (1)移植處理3週後,與空白對照組大鼠ALT、AST、TBIL指標[(637.60±42.38) U/L、(525.80 ±40.20) U/L、(17.26±0.68)μmol/L]比較,BMSCs組[(168.80±8.35) U/L、(352.00±33.64) U/L、(14.12±0.34),mol/L]和UMSCs組[(163.60±7.30) U/L、(339.00±44.94) U/L、(13.96±0.29) μmol/L]均降低,差異均有統計學意義(P＜0.05),ALB指標差異無統計學意義(P＞0.05)；與BMSCs組比較,UMSCs組大鼠ALT、AST、TBIL及ALB指標差異均無統計學意義(p＞0.05).(2)與移植處理前各組ALT、AST、TBIL指標[空白對照組:(337.80±13.97)U/L、(436.40±23.27) U/L、(15.20±0.57) μmol/L; BMSCs組:(337.40±14.10) U/L、(439.40±15.27) U/L、(15.52±0.47) μmol/L;UMSCs組:(337.40±16.21) U/L、(437.20±25.15) U/L、(15.54±0.72).μmol/L]比較,處理3週後BMSCs組和UMSCs組相應指標均降低,空白對照組相應指標均升高,差異均有統計學意義(P＜0.05)；移植處理前後各組大鼠ALB指標差異無統計學意義(P＞0.05).(3)與空白對照組比較,BMSCs組和UMSCs組肝髒炎癥活動度及纖維化程度均減輕,量化計分(空白對照組:13.20±1.79、15.90±5.28;BMSCs組:4.70±1.57、6.00±1.70; UMSCs組:4.30±1.79、5.90±0.82)差異有統計學意義(P＜ 0.05)；UMSCs組與BMSCs組計分差異無統計學意義(P＞0.05).結論 UMSCs和BMSCs移植均可改善CCl4誘導的肝纖維化大鼠的肝功能,減輕肝髒的炎癥活動度及纖維化程度,其中UMSCs的改善效果稍優于BMSCs.
목적 관찰제대간질간세포(UMSCs)화골수간질간세포(BMSCs)대CCl4유도대서간섬유화적치료작용.방법 통과50％ CCl4감람유피하주사10주건립대서간섬유화모형,수궤평균분위UMSCs조、BMSCs조급공백대조조,UMSCs조경미정맥수주1ml UMSCs(2×109/L),BMSCs조수주1 ml BMSCs (2×109/L),공백대조조수주1 ml생리염수,이식처리3주후처사소유대서.추취혈액검측이식처리전후각조대서간공능지표[곡병전안매(ALT)、곡초전안매(AST)、총담홍소(TBIL)、백단백(ALB)],취간장표본소목소-이홍(HE)염색행병리검사급양화계분.결과 (1)이식처리3주후,여공백대조조대서ALT、AST、TBIL지표[(637.60±42.38) U/L、(525.80 ±40.20) U/L、(17.26±0.68)μmol/L]비교,BMSCs조[(168.80±8.35) U/L、(352.00±33.64) U/L、(14.12±0.34),mol/L]화UMSCs조[(163.60±7.30) U/L、(339.00±44.94) U/L、(13.96±0.29) μmol/L]균강저,차이균유통계학의의(P＜0.05),ALB지표차이무통계학의의(P＞0.05)；여BMSCs조비교,UMSCs조대서ALT、AST、TBIL급ALB지표차이균무통계학의의(p＞0.05).(2)여이식처리전각조ALT、AST、TBIL지표[공백대조조:(337.80±13.97)U/L、(436.40±23.27) U/L、(15.20±0.57) μmol/L; BMSCs조:(337.40±14.10) U/L、(439.40±15.27) U/L、(15.52±0.47) μmol/L;UMSCs조:(337.40±16.21) U/L、(437.20±25.15) U/L、(15.54±0.72).μmol/L]비교,처리3주후BMSCs조화UMSCs조상응지표균강저,공백대조조상응지표균승고,차이균유통계학의의(P＜0.05)；이식처리전후각조대서ALB지표차이무통계학의의(P＞0.05).(3)여공백대조조비교,BMSCs조화UMSCs조간장염증활동도급섬유화정도균감경,양화계분(공백대조조:13.20±1.79、15.90±5.28;BMSCs조:4.70±1.57、6.00±1.70; UMSCs조:4.30±1.79、5.90±0.82)차이유통계학의의(P＜ 0.05)；UMSCs조여BMSCs조계분차이무통계학의의(P＞0.05).결론 UMSCs화BMSCs이식균가개선CCl4유도적간섬유화대서적간공능,감경간장적염증활동도급섬유화정도,기중UMSCs적개선효과초우우BMSCs.
Objective To investigate and compare the therapeutic effect of human umbilical cord mesenchymal stem cells (UMSCs) and bone marrow mesenchymal stem cells (BMSCs) on hepatic fibrosis in rats induced by carbon tetrachloride (CCl4).Methods Hepatic fibrosis model of Wistar rats were induced by subcutaneous injection of CCl4 oily mixture continuously for 10 weeks.Then the rats were randomly divided into UMSCs group,BMSCs group and control group.UMSCs group was treated by infusion,of 1 ml UMSCs suspension (2 x 109/L) via the caudal vein,BMSCs group with 1 ml BMSCs suspension,and control group with 1 ml normal saline.The treatment had last for 3 weeks.The blood of the rats was taken to measure liver function before and after the treatment.Also the hepatic tissues were taken to observe and evaluate pathological changes by HE staining.Results The levels of plasma ALT,AST and TBIL were reduced significantly in BMSCs group [(168.80 ±8.35) U/L,(352.00 ±33.64) U/L,(14.12 ±0.34)μmol/L vs.(337.40 ±14.10) U/L,(439.40±15.27) U/L,(15.52 ±0.47) μnoL/L] and UMSCs group [(163.60±7.30) U/L,(339.00 ±44.94) U/L,.(13.96 ±0.29) μnol/L vs.(337.40 ±16.21) U/L,(437.20 ±25.15) U/L,(15.54 ± 0.72) μmol/L] after transplantation,roughly the reverse condition in control group [(637.60±42.38) U/L,(525.80 ±40.20)U/L,(17.26±0.68) μmol/L vs.(337.80±13.97) U/L,(436.40 ± 23.27) U/L,(15.20 ± 0.57) μmol/L],all P ＜ 0.05.However,none of these groups had reduced the level of plasma ALB (P ＞ 0.05),As compared with control group (13.20 ± 1.79,15.90±5.28),both BMSCs group (4.70±1.57,6.00±1.70) and UMSCs group (4.30±1.79,5.90±0.82) obtained better pathological evaluations of the inflammation mobility as well as the degree of hepatic fibrosis (P ＜ 0.05).And there was no significant difference between UMSCs group and BMSCs group (P ＞0.05).Conclusion The transplantation of UMSCs can improve liver function and alleviate liver fibrosis in rats,slightly better than BMSCs.
